Anticardiolipin antibody and anti-β2 glycoprotein I antibody are potential risk markers of ischaemic stroke in Chinese adults. (13th November 2019) - Dong, Shengyong
Abstract: Objectives: aCL and anti-β2 glycoprotein I antibody (aβ2 GPI) are autoantibodies associated with thromboembolic diseases. Here we investigated whether they are correlated with ischaemic cardiovascular disease in a Chinese population. Methods: Serum total aCL and aβ2 GPI isotypes (IgA, IgG or IgM, separately) were measured in 11 015 Chinese adults. Differences of antibody level between disease and non-disease groups were examined by t -test. The correlation between antibody and ischaemic cardiovascular disease was determined by logistic regression analysis. Performance of risk prediction models employed aCL or aβ2 GPI isotypes was evaluated by C statistic, net reclassification improvement index and integrated discrimination improvement. Results: Total aCL and aβ2 GPI isotypes maintained low levels and increased with increasing age except total aCL and aβ2 GPI IgG in participants older than 70 years. When distinguishing ischaemic cardiovascular disease by coronary heart disease (CHD) and ischaemic stroke, the stroke group had higher levels of aCL and aβ2 GPI isotypes than the non-stroke group, while the CHD group only had a slightly higher aβ2 GPI IgG than non-CHD groups. aCL and aβ2 GPI were positively correlated with stroke but not with CHD, and improved the performance of conventional risk factors for stroke risk prediction, with C statistic from 0.769 (95% CI 0.744, 0.793) to 0.777 (95% CI 0.754, 0.800) (aβ2 GPI IgG, P = 0.0091), and 0.778 (95% CI 0.754, 0.801) (aβ2 GPI IgA, P = 0.0793). Stroke risk could be better reclassified by aCL and aβ2 GPI, in association with both net reclassification improvement and integrated discrimination improvement statistics ( P < 0.05). Conclusion: aCL and aβ2 GPI are associated with ischaemic stroke and have added value for stroke risk prediction.